Silo pharma, inc. expands scientific advisory board with appointment of dr. peter hendricks of university of alabama at birmingham

New jersey, dec. 07, 2020 (globe newswire) -- silo pharma, inc. (otcqb: silo) a developmental stage biopharmaceutical company focused on the use of psilocybin as a therapeutic, today announced that its board of directors has named behavioral health expert dr. peter hendricks, ph.d. to its newly formed scientific advisory board.

SILO Ratings Summary

SILO Quant Ranking